Lakewood-Amedex Biotherapeutics INC. (LABT) — SEC Filings
Latest SEC filings for Lakewood-Amedex Biotherapeutics INC.. Recent EFFECT filing on Apr 20, 2026. AI-decoded analysis of earnings, risk factors, and insid
View Lakewood-Amedex Biotherapeutics INC. on SEC EDGAR
Overview
Lakewood-Amedex Biotherapeutics INC. (LABT) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a EFFECT filed on Apr 20, 2026: Lakewood-Amedex Biotherapeutics Inc. filed an EFFECT form with the SEC on April 20, 2026, indicating the effectiveness of a registration statement. The filing, with accession number 9999999995-26-001238, relates to Act 33 and File No. 333-292664. The company's mailing and business address is 8031 Co
Sentiment Summary
Across 3 filings, the sentiment breakdown is: 1 bearish, 2 neutral. The dominant filing sentiment for Lakewood-Amedex Biotherapeutics INC. is neutral.
Filing Type Overview
Lakewood-Amedex Biotherapeutics INC. (LABT) has filed 1 EFFECT, 2 S-1/A with the SEC between Apr 2026.
Recent Filings (3)
-
Lakewood-Amedex Biotherapeutics SEC Filing Effectiveness
— EFFECT · Apr 20, 2026 Risk: low
Lakewood-Amedex Biotherapeutics Inc. filed an EFFECT form with the SEC on April 20, 2026, indicating the effectiveness of a registration statement. The filing, -
Lakewood-Amedex Biotherapeutics Files S-1/A Amendment
— S-1/A · Apr 6, 2026 Risk: medium
Lakewood-Amedex Biotherapeutics Inc. filed an S-1/A amendment on April 6, 2026, to register securities. The filing includes various exhibits such as consents of -
Lakewood-Amedex Pursues Nasdaq Direct Listing, Raises $7.5M in Private Placement
— S-1/A · Apr 1, 2026 Risk: high
Lakewood-Amedex Biotherapeutics Inc. (LABT) is pursuing a direct listing on the Nasdaq Capital Market for 4,689,177 shares of common stock, with no firm-commitm
Frequently Asked Questions
What are the latest SEC filings for Lakewood-Amedex Biotherapeutics INC. (LABT)?
Lakewood-Amedex Biotherapeutics INC. has 3 recent SEC filings from Apr 2026, including 2 S-1/A, 1 EFFECT. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of LABT filings?
Across 3 filings, the sentiment breakdown is: 1 bearish, 2 neutral. The dominant sentiment is neutral.
Where can I find Lakewood-Amedex Biotherapeutics INC. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Lakewood-Amedex Biotherapeutics INC. (LABT) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.